GlaxoSmithKline plc (NYSE:GSK) has been given a consensus recommendation of “Hold” by the twenty-one analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, sixteen have given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $43.00.
GSK has been the subject of several analyst reports. Zacks Investment Research upgraded GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Tuesday, April 23rd. Cowen restated a “hold” rating and issued a $45.00 price objective on shares of GlaxoSmithKline in a report on Monday, June 10th. Shore Capital cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Finally, UBS Group cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Friday, February 22nd.
Shares of NYSE GSK opened at $40.12 on Friday. The stock has a market capitalization of $99.52 billion, a PE ratio of 12.70, a P/E/G ratio of 2.08 and a beta of 0.74. The company has a debt-to-equity ratio of 6.92, a current ratio of 0.72 and a quick ratio of 0.48. GlaxoSmithKline has a fifty-two week low of $36.41 and a fifty-two week high of $42.32.
The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a $0.4953 dividend. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $1.98 annualized dividend and a yield of 4.94%. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 61.71%.
In other news, Director Plc Glaxosmithkline bought 325,000 shares of the business’s stock in a transaction that occurred on Monday, April 22nd. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $5,850,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.00% of the company’s stock.
A number of large investors have recently modified their holdings of GSK. Boston Partners acquired a new stake in GlaxoSmithKline during the fourth quarter worth approximately $65,234,000. Norges Bank acquired a new stake in GlaxoSmithKline during the fourth quarter worth approximately $17,275,000. Two Sigma Investments LP acquired a new stake in GlaxoSmithKline during the fourth quarter worth approximately $15,936,000. Deutsche Bank AG lifted its position in GlaxoSmithKline by 221.0% during the fourth quarter. Deutsche Bank AG now owns 529,309 shares of the pharmaceutical company’s stock worth $20,222,000 after acquiring an additional 364,431 shares during the last quarter. Finally, Millennium Management LLC lifted its position in GlaxoSmithKline by 612.0% during the fourth quarter. Millennium Management LLC now owns 365,325 shares of the pharmaceutical company’s stock worth $13,959,000 after acquiring an additional 314,016 shares during the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: What is the Federal Reserve?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.